This website is for information purposes only; we are not diagnosing, treating, curing, mitigating, or preventing any disease or medical condition by providing the information contained herein. Before beginning any natural treatment regimen, seek the advice of a licensed healthcare professional.
NATURAL PROTECTION FROM THE VIRUS AND SPIKE PROTEIN
The very dangerous spike protein is a new, extremely concerning problem that hasn’t been studied long. Just as learning the vaccine’s adverse events has barely begun compared to the standard five to fifteen years, they are usually examined. Everything is a new science, and we need a lot more information in all areas.
There is some information on how to protect ourselves from the contagious spike protein, and it is not hard to do, nor is it very costly. These recommendations also have many other excellent health benefits. These recommendations are for those that have trillions of spike proteins circulating through their body after injection of the gene therapy they are calling a vaccine, or if you have close contact with those injected.
What Helps Protect Against the Spike Protein?
10,000mg of Vitamin C per day – Doctors in China are curing Covid-19 in three days with 35,000mg I.V vitamin C a day. Pharma does not want you to know. If there were an effective treatment, they would not get emergency approval for the vaccine. They have suppressed this information through the most extreme censorship we have seen in U.S. history. But some doctors believe high doses of vitamin C will protect against the toxic spike protein. You should take 2,000mg 5x a day.
200mcg of Selenium per day. The bone marrow makes white blood cells. Selenium makes your body produce more white blood cells and supports your bone marrow. Selenium helps your liver create glutathione which coats the cells in your body, protecting them from damaging effects. Selenium supplementation restores the antioxidative capacity and prevents cell damage in bone marrow stromal cells in vitro.
Pine Needles – Several doctors have stated that Suramin, an isolated compound initially derived from an extract of pine needle oil, is an effective antidote to the spike protein. It appears to be effective in inhibiting the inappropriate replication and modification of RNA and DNA. We will be doing more research to verify the information, but the doctors have been very optimistic about the effects. We think it is too soon to use the word “antidote” since more information is needed.
Blood clots are one of the adverse events of extreme concern to many doctors and scientists. Suramin also showed inhibitory effects against components of blood coagulation.
Here is some science from the National Library of Medicine: The best extraction method to obtain high levels of proanthocyanidins and antioxidative extract from pine needles in hot water. It would be possible to develop functional foods proving the antioxidative ability of hydrothermal extract through animal testing.
Prevention of SARS-Cov-2
CBD – Studies show CBD inhibits SarsCov2. The science is out on CBD and SarsCov2, and we are looking to see if it plays a role in helping to protect against the spike protein.
Dandelion – A new study appeared in bioRxiv showing the Common dandelion efficiently blocks the interaction between ACE2 cell surface receptor and SARS-CoV-2 spike protein.
Vitamin D – Under construction be back shortly
Vitamin C – 2,000mg Vit C 5x a day
Selenium – 200mc daily
Melatonin – 10mg at bedtime
MORE DETAILS ARE ON OUR PROTOCOL PAGE
The vaccinated are shedding the spike protein.
Right in the Pfizer clinical trial protocol, that is public information. We highlighted the relevant parts at the bottom of this article, but we suggest you read the document directly from the source.
PAY ATTENTION HERE:
Occupational exposure is “unplanned direct contact with the study intervention.” Again, that means exposure by inhalation or skin contact.
8.3.5.3. Occupational Exposure
An occupational exposure occurs when a person receives unplanned direct contact with the study intervention, which may or may not lead to the occurrence of an AE. Such persons may include healthcare providers, family members, and other roles that are involved in the trial participant’s care.8.3.5.2. Exposure During Breastfeeding
An exposure during breastfeeding occurs if:
• A female participant is found to be breastfeeding while receiving or after discontinuing study intervention.
• A female is found to be breastfeeding while being exposed or having been exposed to study intervention (ie, environmental exposure). An example of environmental exposure during breastfeeding is a female family member or healthcare provider who reports that she is breastfeeding after having been exposed to the study intervention by inhalation or skin contact.
PFIZER DOCUMENTS – CLINICAL TRIAL – they removed the link, so we cannot link to it, but it was copied verbatim. We will look for another link.
8.3.5.1. Exposure During Pregnancy
An EDP occurs if:
• A female participant is found to be pregnant while receiving or after discontinuing study intervention.
• A male participant who is receiving or has discontinued study intervention exposes a
female partner before or around the time of conception.
• A female is found to be pregnant while being exposed or having been exposed to study intervention due to environmental exposure. Below are examples of environmental exposure during pregnancy:
• A female family member or healthcare provider reports that she is pregnant after having been exposed to the study intervention by inhalation or skin contact.
• A male family member or healthcare provider who has been exposed to the study intervention by inhalation or skin contact then exposes his female partner prior to or around the time of conception.
The investigator must report EDP to Pfizer Safety within 24 hours of the investigator’s awareness, irrespective of whether an SAE has occurred. The initial information submitted PF-07302048 (BNT162 RNA-Based COVID-19 Vaccines) Protocol C4591001
Page 63
should include the anticipated date of delivery (see below for information related to termination of pregnancy).
• If EDP occurs in a participant or a participant’s partner, the investigator must report this information to Pfizer Safety on the Vaccines SAE Report Form and an EDP Supplemental Form, regardless of whether an SAE has occurred. Details of the pregnancy will be collected after the start of study intervention and until 6 months after the last dose of study intervention.
• If EDP occurs in the setting of environmental exposure, the investigator must report information to Pfizer Safety using the Vaccines SAE Report Form and EDP Supplemental Form. Since the exposure information does not pertain to the participant enrolled in the study, the information is not recorded on a CRF; however, a copy of the completed Vaccines SAE Report Form is maintained in the investigator site file. Follow-up is conducted to obtain general information on the pregnancy and its outcome for all EDP reports with an unknown outcome. The investigator will follow the pregnancy until completion (or until pregnancy termination) and notify Pfizer Safety of the outcome as a follow-up to the initial EDP Supplemental Form. In the case of a live birth, the structural integrity of the neonate can be assessed at the time of birth. In the event of a termination, the reason(s) for termination should be specified and, if clinically possible, the structural integrity of the terminated fetus should be assessed by gross visual inspection (unless preprocedure test findings are conclusive for a congenital anomaly and the findings are reported). Abnormal pregnancy outcomes are considered SAEs. If the outcome of the pregnancy meets the criteria for an SAE (ie, ectopic pregnancy, spontaneous abortion, intrauterine fetal demise, neonatal death, or congenital anomaly), the investigator should follow the procedures for reporting SAEs. Additional information about pregnancy outcomes that are reported to Pfizer Safety as SAEs follows:
• Spontaneous abortion including miscarriage and missed abortion;
• Neonatal deaths that occur within 1 month of birth should be reported, without regard to causality, as SAEs. In addition, infant deaths after 1 month should be reported as SAEs when the investigator assesses the infant death as related or possibly related to exposure to the study intervention. Additional information regarding the EDP may be requested by the sponsor. Further follow-up of birth outcomes will be handled on a case-by-case basis (eg, follow-up on preterm infants to identify developmental delays). In the case of paternal exposure, the investigator will provide the participant with the Pregnant Partner Release of Information Form to deliver to his partner. The investigator must document in the source documents that the participant was given the Pregnant Partner Release of Information Form to provide to his partner.
PF-07302048 (BNT162 RNA-Based COVID-19 Vaccines)
Protocol C4591001
Page 64
8.3.5.2. Exposure During Breastfeeding
An exposure during breastfeeding occurs if:
• A female participant is found to be breastfeeding while receiving or after discontinuing study intervention.
• A female is found to be breastfeeding while being exposed or having been exposed to study intervention (ie, environmental exposure). An example of environmental exposure during breastfeeding is a female family member or healthcare provider who reports that she is breastfeeding after having been exposed to the study intervention by inhalation or skin contact. The investigator must report exposure during breastfeeding to Pfizer Safety within 24 hours of the investigator’s awareness, irrespective of whether an SAE has occurred. The information must be reported using the Vaccines SAE Report Form. When exposure during breastfeeding occurs in the setting of environmental exposure, the exposure information does not pertain to the participant enrolled in the study, so the information is not recorded on a CRF. However, a copy of the completed Vaccines SAE Report Form is maintained in the
investigator site file.
An exposure during breastfeeding report is not created when a Pfizer drug specifically approved for use in breastfeeding women (eg, vitamins) is administered in accord with authorized use. However, if the infant experiences an SAE associated with such a drug, the SAE is reported together with the exposure during breastfeeding.
8.3.5.3. Occupational Exposure
An occupational exposure occurs when a person receives unplanned direct contact with the study intervention, which may or may not lead to the occurrence of an AE. Such persons may include healthcare providers, family members, and other roles that are involved in the trial participant’s care.
The investigator must report occupational exposure to Pfizer Safety within 24 hours of the investigator’s awareness, regardless of whether there is an associated SAE. The information must be reported using the Vaccines SAE Report Form. Since the information does not pertain to a participant enrolled in the study, the information is not recorded on a CRF; however, a copy of the completed Vaccines SAE Report Form is maintained in the investigator site file.
Current Prevention of COVID-19: Natural Products and Herbal Medicine – under construction
Natural products inhibiting human coronavirus.
Table 2
Natural products potentially effective for COVID-19.
| Natural Product | Inhibited Virus | Drug Targets/Relevant Signaling | Mechanism of Action | Ref. |
|---|---|---|---|---|
|
|
| Block MERS- CoV entry using pre-and post-attachment assay – also known as Chinese sage, red sage root, and the Chinese herbal Dan Shen. | |
|
|
|
| |
|
|
|
| |
|
|
| | |
|
|
|
| |
|
|
|
| |
|
|
| Inhibition of 3CLPro, IC50: 3 µM | |
|
|
| Blocking 3CLPro function, IC50: 7 µM | |
|
|
|
| |
| Daidzin |
|
|
| |
| Genistein | ||||
| Formononetin | ||||
| Biochanin A | ||||
|
|
|
| |
| 10-Hydroxyusambarensine | SARS-CoV-2 | 3CL protein | High binding affinity to 3CLpro tested by tested by molecular docking | (Gyebi et al., 2020) |
| ||||
| 22-Hydroxyhopan-3-one | ||||
|
|
|
| |
| ||||
|
|
|
|
